PHST Pharsight Corp (MM)

Dr. Laurent Claret Will Present Case Studies on the Value of Drug-Disease Modeling to Predict Efficacy and Survival Benefits of Anticancer Agents MOUNTAIN VIEW, Calif., June 12 /PRNewswire-FirstCall/ -- Pharsight Corporation (NASDAQ:PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Laurent Claret, Ph.D., senior scientist, Pharsight Strategic Consulting Services, will speak to members of the pharmaceutical and biotechnology industries attending the Population Approach Group in Europe (PAGE) 17th Annual Meeting. The PAGE meeting will be held at the Medical School of Marseille in Marseilles, France from June 18-20, 2008. Dr. Claret will present two oncology case studies during a dedicated conference session on applications in model-based development: -- June 18: A Modeling Framework to Simulate Xeloda Dose Intensity and Survival in Colorectal Cancer. Dr. Claret will present this case study as part of an oral conference session on the strategic use of modeling and simulation in oncology. The session will include applied examples of drug-disease modeling and will describe research on how quantitative, model-based approaches have been used to support dosing decisions of anticancer therapies in clinical practice. Rene Bruno, Ph.D., managing director, Pharsight Strategic Consulting Services, Europe, serves as conference chair for the oncology session. -- June 19: Modeling and Simulation to Assess the Use of Change in Tumor Size as Primary Endpoint in Phase II Studies in Oncology. Dr. Claret will present this case study in collaboration with Pharsight's client, a global pharmaceutical company, as part of a poster session on model-based applications in oncology. The session will describe research on a number of model-based approaches to support drug development in oncology, including tumor progression modeling and clinical trial simulations to predict efficacy and survival benefit of anticancer agents. Dr. Claret and Dr. Bruno also contributed to a model-based analysis of tumor size measurements obtained in clinical oncology studies involving combination chemotherapy, as part of an ongoing collaboration between Pharsight and the University of Aix-Marseille School of Pharmacy. This analysis will be presented by Pharsight colleagues at the University of Aix-Marseille as part of the PAGE poster session on model-based applications in oncology. "Model-based drug development continues to show value for enhancing understanding of complex diseases in quantitative terms, and for improving the confidence of drug development decisions," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Application of drug-disease models to simulate expected clinical response of new anticancer therapies can support critical oncology program strategies, particularly in light of the high failure rate in late-stage trials. The use of predictive drug-disease models can serve as a quantitative framework to support programmatic decision-making and enhance study design decisions. Pharsight is pleased to continue its active participation at the PAGE Annual Meeting, this year as a main conference sponsor, and we look forward to sharing our experience with industry colleagues and fellow practitioners of modeling and simulation." Additional information about PAGE can be found at http://www.page-meeting.org/. About Pharsight Corporation Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products. Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com/. Registered Trademarks and Trademarks Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this document are trademarks or registered trademarks of their respective companies or organizations. DATASOURCE: Pharsight Corporation CONTACT: Media, Steve DiMattia or Donald Takaya, +1-646-201-5445, or Investors, Douglas Sherk or Matthew Selinger, +1-415-896-6820, all of EVC Group, for Pharsight Corporation Web site: http://www.pharsight.com/

Copyright